QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
Filtered by 'Strategic Partnerships' ×
In the new era of clinical development, decisions are all data driven, and the mistakes that add millions of dollars to drug development projects will soon be a distant memory.
Read More
Ray Huml
Annie Bing
When clinical research sites join networks, they can leverage the expertise of the collective, generating real benefits for sponsors.
Read More
Marie Lux
Paul Harney
Why biopharma companies need to build fully collaborative patient support programs to improve both patient care and market share.
Read More
Robert Taylor
To improve probability of success and to stay relevant in a tough European market, biopharma companies need a new commercial partnering approach.
Read More
John Procter
A joint working approach allows biopharma to pool resources and collaborate with the NHS to improve patient care.
Read More
At the start of the 2016 BIO International Convention, Laura Marquis offers some quick advice for emerging biopharma companies.
Read More
Jane Eisner
In the pharmaceutical industry we talk a lot about two groups: ‘Big Pharma,’ the global giants with massive networks and deep pockets that extend across virtually every therapeutic category; and ‘emerging biopharma,’ the agile start-ups that may have limited resources but they also have huge potential to disrupt the marketplace with innovative new products. But what about the companies in-between? ‘Mid-size biopharma’ companies aren’t big enough to be considered big pharma, but they’ve outgrown their ‘biotech’ badge, and they make up a large portion of the marketplace. These mid-sized companies face a lot of challenges as they grow. They generally have well-known products and specific brand leadership that they want to maintain, but they also have their eye set on expanding...
Read More
Helena Zhang
More and more regulators are demanding real-world outcomes data after medicinal product authorization. Even the most innovative clinical trials require outcome studies to further demonstrate the safety, effectiveness and risk/benefit evaluation of the treatment in diverse populations in China. However, our clinical trial models at present often lack the processes and resources to gather this data. This gap can only be closed if we as an industry more proactively pursue the collection of evidence-based data through observational studies as part of our broader trial initiatives. By investing time and resources into real world late phase (RWLP) studies, we can broaden the medical research horizon, stimulate evidence-based medicine, and strengthen partnership between the medical community...
Read More